101MS402 TYGRIS - Tysabri Global Observational Program in Safety

101MS402 TYGRIS - Tysabri Global Observational Program in Safety

Type of Study
Neuroscience - Multiple Sclerosis
Location
Cherry Hill Campus
Short Description

Primary Study Objective:
 

  • The primary study objective is to determine the incidence and pattern of serious infections, malignancies and other serious adverse events (SAEs) in patients with Multiple Sclerosis (MS) treated with TYSABRI® (natalizumab).
Status
Open
Principal Investigator
Lily Jung, MD
Eligibility Notes

Those who qualify:
 

  • Patients who have received ≥1 to ≤3 infusions of TYSABRI enrolled in the TOUCH Prescribing Program

Follow up:
 

  • Enrollment is to coincide with a routine clinical visit to the prescribing physician
  • Future visits for the study will occur at 6-month intervals for 5 years following the first TYSABRI infusion
  • Collection of a blood sample is encouraged at the time of enrollment
Contact Name
Brooke Amos, Research Assistant
Phone
(206) 320-2599
Email
brooke.amos@swedish.org